<DOC>
	<DOCNO>NCT00217477</DOCNO>
	<brief_summary>RATIONALE : Paricalcitol may cause cancer cell look like normal cell , grow spread slowly . Drugs use chemotherapy , gemcitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving paricalcitol together gemcitabine may effective treatment cancer . PURPOSE : This phase I trial study side effect best dose paricalcitol give together gemcitabine treat patient advanced cancer .</brief_summary>
	<brief_title>Paricalcitol Gemcitabine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) paricalcitol give gemcitabine patient advanced malignancy . Secondary - Determine safety toxicity regimen patient . - Determine pharmacokinetics regimens patient . - Determine clinical outcome ( overall survival best overall response ) patient treat regimen . OUTLINE : This dose-escalation , open-label study . Patients receive gemcitabine IV 80 minute day 1 , 8 , 15 paricalcitol IV 15 minute day 7 14 course 1 . Beginning course 2 , patient receive paricalcitol IV 15 minute day 1 , 8 , 15 gemcitabine IV 80 minute day 2 , 9 , 16 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paricalcitol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A minimum 6 patient treated MTD . After completion study treatment , patient follow survival . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance malignancy Metastatic unresectable disease Standard curative palliative measure exist longer effective No known brain metastases Patients previously treat brain metastasis eligible provide recovered prior treatment PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 3.0 time upper limit normal Renal Creatinine ≤ 2.0 mg/dL Corrected calcium ≤ 10.5 mg/dL Prior single confirm urolithiasis allow provide patient free stone formation ≥ 5 year No calculus urinary tract kidney ultrasound biopsy image study Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 3 month completion study treatment No ongoing active infection No psychiatric illness social situation would preclude study compliance No history allergic reaction attribute compound similar chemical biological composition study drug No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover Surgery Not specify Other Curative therapy condition associate risk renal stone ( e.g. , hyperparathyroidism , bladder dysfunction , obstructive uropathy ) allow provided patient free stone formation ≥ 5 year No concurrent digoxin No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>